Veterans Health Library

Mercaptopurine is an antineoplastic agent used to treat acute lymphocytic leukemia.

Select a medication above to begin.

Monitoring the adverse reactions is recommended (FDA, 2021; Hirose et al., 2016). Iloperidone is an atypical antipsychotic drug used for acute treatment of adults with schizophrenia (Buckley et al., 2010). According to the FDA-approved medication label for iloperidone (FANAPT), CYP2D6 poor metabolizers are exposed to more iloperidone than extensive metabolizers, and their dosage should be cut in half (Whirl-Carrillo et al., 2012). CYP2D6 poor metabolizers lead to higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reducing the dose by half is recommended (FDA, 2021; Nnadi and Malhotra, 2008; De Leon, 2009).

Other Medical Problems

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. Irinotecan dose reductions are recommended for UGT1A1 *28/*28 or UGT1A1 PM patients, beginning at 70% of the starting dose and increasing as tolerated, driven by neutrophil count (Whirl-Carrillo et al., 2012). Higher systemic active metabolite concentrations and a higher risk of cenforce 200 mg adverse reactions are associated with UGT1A1 *28/*28 (poor metabolizers) (severe neutropenia). Starting dose reduction by one level and adjusting the dosage based on individual patient tolerance is recommended (FDA, 2021; Innocenti and Ratain, 2006). Lofexidine is a centrally acting alpha2-adrenergic agonist that has been used to treat high blood pressure in the past but is now most widely used to treat the opioid withdrawal syndrome in adults to assist abrupt opioid discontinuation. The CPIC Dosing Guideline states that patients with TPMT or NUDT15 poor metabolizers should consider a different agent or a drastic reduction in mercaptopurine dosage.

Patients who are intermediate metabolizers of TPMT or NUDT15 should start at 30–80% of the target dose (Relling et al., 2019; Zgheib et al., 2017).

• Flibanserin's mechanism involves increasing dopamine and norepinephrine and decreasing serotonin levels.
• It does not address libido caused by relationship issues or physical health problems.
• Flibanserin was once controversial due to debates over its effectiveness.
• It is not suitable for women taking certain antidepressants due to drug interactions.
• The medication has warnings for severe hypotension and syncope.
• Patients are advised to avoid alcohol consumption completely while on the drug.
• Flibanserin's approval was considered a breakthrough for female sexual health.
• Insurance coverage for flibanserin varies and can be limited.
• The drug's marketing emphasizes the importance of patient counseling.

According to the Dutch Pharmacogenetics Working Group, choosing an alternative drug or decreasing the initial dose of mercaptopurine for patients with NUDT15 poor metabolizers, and reducing the initial dose for NUDT15 intermediate metabolizer patients are recommended (Whirl-Carrillo et al., 2012).

Results In As Little As 4 Weeks

Although the pharmacokinetics of lofexidine (LUCEMYRA) have not been routinely tested in patients who do not express CYP2D6, it is probable that sensitivity to the medication will be increased in these patients (Whirl-Carrillo et al., 2012). In CYP2D6 poor metabolizers result in higher systemic concentrations and higher adverse reaction risk. Orthostatic hypotension and bradycardia monitoring are recommended (FDA, 2021; Mehta and Banerji, 2020). Meclizine is a histamine H1 antagonist that is used to treat motion sickness symptoms including nausea, vomiting, and dizziness. The FDA-approved drug label for meclizine (ANTIVERT) was indicated that CYP2D6 genetic polymorphism can play a role in meclizine exposure variability as the dominant metabolizing enzyme (Whirl-Carrillo et al., 2012).

Approval Year

CYP2D6 ultrarapid, intermediate, or poor metabolizers may influence systemic concentrations. Monitoring the adverse reactions and clinical effects are recommended (FDA, 2021, Hirose et al., 2016). Meloxicam is an NSAID that is used for treatment of osteoarthritis, rheumatoid arthritis in adults, and juvenile rheumatoid arthritis in children. According to the FDA-approved drug label for meloxicam (QMIIZ ODT), consideration of dose reduction, and monitoring the adverse effects are recommended in adult patients who are known or suspected poor CYP2C9 metabolizers (Whirl-Carrillo et al., 2012; Bae et al., 2011). CYP2C9 poor metabolizers lead to higher systemic concentrations. The guideline also recommends choosing an alternative drug or decreasing the initial dose of mercaptopurine for patients with TPMT low metabolizers and reducing the initial dose for patients who are TPMT intermediate metabolizers (Whirl-Carrillo et al., 2012; Dean and Kane, 2012). According to the FDA guideline, TPMT and/or NUDT15 intermediate or poor metabolizers alter systemic active metabolite concentration and dosage requirements and lead to higher adverse reaction risk (myelosuppression).

IMPORTANT WARNING:

Consideration of dose reduction is recommended (FDA, 2021). Metoclopramide used in the treatment of gastroesophageal reflux disorder, inhibition of nausea and vomiting, and to promote gastric emptying as an antiemetic agent and dopamine D2 antagonist. Metoclopramide (REGLAN) is used as a short-term treatment option in gastroesophageal reflux in adult patients who have not responded to conventional therapy. Drug elimination is decreased in patients with CYP2D6 poor metabolizers, potentially raising the risk of adverse reactions, a reduced dose of the metoclopramide should prescribed to the patients (Whirl-Carrillo et al., 2012; Bae et al., 2020). Higher systemic concentrations and adverse reaction risk could associate with CYP2D6 poor metabolizers (FDA, 2021). Initial dosages should be decreased in poor metabolizers; poor metabolizers tolerate 10% or less of the prescribed dose.

Mechanism of action

According to the FDA-approved drug label for flibanserin (ADDYI), patients with poor metabolizers of CYP2C19 had increased exposure to the drug as compared to extensive metabolizers. Syncope was observed in one patient with a poor metabolizer (Whirl-Carrillo et al., 2012). The FDA label also has some recommendations for the influence of CYP2D6 and CYP2C9 on flibanserin exposure. CYP2C19 poor metabolizers may result higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions (FDA, 2021; Dean, 2019b).

Sample Use Guides

Flurbiprofen is used for the treatment of osteoarthritis and rheumatoid arthritis (RA) signs and symptoms as a prescription NSAID. In the CPIC Dosing Guideline for celecoxib, flurbiprofen, ibuprofen, and lornoxicam, initiating therapy with the lowest and 25–50% of the lowest recommended starting dose are recommended for CYP2C9 intermediate and poor metabolizers, respectively (Theken et al., 2020). CYP2C9 poor metabolizers result in higher systemic concentrations. Use of reduced dosage is recommended (FDA, 2021; Dean, 2019c). Fluorouracil is a pyrimidine derivative that is used to treat basal cell carcinomas and as a palliative cancer drug injection. Tolerability can necessitate dose reductions for intermediate metabolizers.

Real Experiences. Real Reviews.

Systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation) are altered in patients with CYP2D6 ultrarapid, normal, intermediate, or poor metabolizers. It may not achieve adequate concentrations to achieve a therapeutic effect in ultrarapid metabolizers. The recommended dosages are based on CYP2D6 metabolizer status. In intermediate and weak CYP2D6 metabolizers, coadministration with strong CYP3A inhibitors is not recommended (FDA, 2021; Balwani et al., 2016). Erdafitinib is an inhibitor of fibroblast growth factor receptor tyrosine kinase used to locally advanced or metastatic urothelial carcinoma treatment.

Does Addyi interact with other medicines (drug interactions)?

The FDA-approved label introduces erdafitinib (BALVERSA) as a kinase inhibitor that is used for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations. It is predicted that plasma concentrations may be higher in patients with the CYP2C9*3/*3 genotype and patients who are known or suspected to have CYP2C9*3/*3 genotypes are better to follow for increased adverse reactions (Whirl-Carrillo et al., 2012; Hattinger et al., 2020). Higher systemic concentrations and a higher risk of adverse reactions can result from CYP2C9 *3/*3 (poor metabolizers). Monitoring for ADRs is recommended (FDA, 2021). Flibanserin is used in the treatment of selected premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as a 5-HT receptor modulator. For both genes, intermediate metabolizers may necessitate more drastic dosage reductions (FDA, 2021).

Increasing the starting daily dose and to monitoring efficacy in CYP2C19 ultrarapid metabolizer is recommended in the CPIC Dosing Guideline for omeprazole, lansoprazole, pantoprazole.

How much does Addyi (flibanserin) cost?

For patients who are DPYD poor metabolizers with an activity score of 0, the CPIC Dosing Guideline for 5-fluorouracil and capecitabine suggests an alternative choice. If an alternative treatment is not considered a viable therapeutic choice for those who are slow metabolizers with an activity score of 0.5, 5-fluorouracil or capecitabine should be prescribed at a greatly reduced dosage with early therapeutic drug control. Patients with an activity score of 1 to 1.5 who are intermediate metabolizers should achieve a 50% dosage reduction. Patients with the 2846A>T and 2846A>T genotypes can require a dose reduction of more than 50% (Amstutz et al., 2018). DPYD intermediate or poor metabolizer leads to raising the adverse reaction risk (severe, life-threatening, or fatal toxicities).

Label Warnings

No dosage has proven safe in poor metabolizers and there is insufficient evidence to make a dosage recommendation in intermediate metabolizers. If you experience early-onset or unusually high toxicity, stop taking it (FDA, 2021; Matsusaka and Lenz, 2015). Gefitinib (IRESSA) is recommended for the first treatment of patients with metastatic non-small cell lung cancer (NSCLC) with exon 19 deletions or exon 21 (L858R) replacement mutations of epidermal growth factor receptor (EGFR) according to the FDA-approved drug label. The label also mentions the relevance of understanding the CYP2D6 phenotype in clinical practice, though CYP2D6 testing is not listed (Whirl-Carrillo et al., 2012). CYP2D6 poor metabolizer is led to higher systemic concentrations and higher adverse reaction risk. In the treatment of Helicobacter pylori (H.

• Flibanserin's journey from failed antidepressant to HSDD treatment is unique.
• Its development cost hundreds of millions of dollars over two decades.
• The FDA initially rejected it in 2010 and 2013 due to safety/efficacy concerns.
• Final 2015 approval came with the stringent REMS and boxed warning.
• The approval process involved patient testimony and advocacy efforts.
• It is classified as a multifunctional serotonin agonist and antagonist (MSAA).
• Does not bind significantly to dopamine, norepinephrine, or histamine receptors.
• Binding affinity is highest for serotonin 5-HT1A and 5-HT2A receptors.
• Its metabolite, 6-hydroxy-flibanserin, is inactive.

pylori) infection and erosive esophagitis with CYP2C19 rapid and natural metabolizers, increasing the dose after initiation with the usual starting daily dose may be considered.

For chronic therapy (>12 weeks) and efficacy reached, a 50% reduction in daily dose is recommended for intermediate and low metabolizers (Lima et al., 2020).